Cost–effectiveness of statins revisited: lessons learned about the value of innovation

Lindgren, Peter

doi:10.1007/s10198-011-0315-1

Cited by 18 publications

(26 citation statements)

References 36 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…12 Assuming constant sales of simvastatin through 2018, the Swedish study estimated the overall social value for the period 1987-2018 at 0.7-1.6 billion euros, of which 94-97 percent was consumer value. Related research on antihypertensive, cancer, and HIV drugs has also suggested a large social value that is primarily captured by consumers.…”

Section: Introductionmentioning

confidence: 99%

The Large Social Value Resulting From Use Of Statins Warrants Steps To Improve Adherence And Broaden Treatment

et al. 2012

View full text Add to dashboard Cite

Statins are considered a clinically important breakthrough for the treatment of cardiovascular disease. However, their social value at the US population level has not previously been studied. From an economic perspective, social value measures the quantity of resources--in monetary terms--that society would be willing to give up in order to retain the survival gains resulting from statin therapy. Using combined population and clinical data, this article calculates statins' social value to consumers, or the value of survival benefits above actual payments for the drug, and to producers, or drug revenues, for the period 1987-2008. National survey data suggest that statin therapy reduced low-density lipoprotein levels by 18.8 percent, which translated into roughly 40,000 fewer deaths, 60,000 fewer hospitalizations for heart attacks, and 22,000 fewer hospitalizations for strokes in 2008. For people starting statin therapy in 1987-2008, consumers captured $947.4 billion (76 percent) of the total social value of the survival gains. Even greater consumer benefits could be achieved in the future if statins were prescribed in full compliance with cholesterol guidelines and patients adhered to prescribed regimens. In addition, statin costs are declining because of patent expirations. Policy makers should consider interventions at the patient and provider levels to encourage both therapy for untreated patients with high cholesterol and greater adherence after therapy is initiated.

show abstract

Section: Introductionmentioning

confidence: 99%

The Large Social Value Resulting From Use Of Statins Warrants Steps To Improve Adherence And Broaden Treatment

et al. 2012

View full text Add to dashboard Cite

show abstract

“…The example of medicines in prevention of cardiovascular disease and in breast cancer treatment Life-years gained is also the key outcome measure in studies that have estimated the value of tamoxifen and trastuzumab for the treatment of breast cancer, and lipid-lowering and antihypertensive treatments administered as primary and secondary prevention in cardiovascular disease (Lindgren and Jönsson, 2012, Lundqvist et al, 2013a, Lundqvist et al, 2013b. These studies have included estimates of quality-adjusted life expectancy in the ex-post valuation of new medicines primarily introduced to increase survival.…”

Section: 2mentioning

confidence: 99%

“…Lindgren and Jönsson, (2012) estimated the value of lipid-lowering therapy using simvastatin from its launch in Sweden in 1987 until 2008, based on registry data, and forecasted its continued use to 2028. This study showed a steep increase in the number of individuals commencing treatment with simvastatin when the price was reduced as a consequence of patent expiration(-90%).…”

Section: 3mentioning

confidence: 99%

Valuing new medicines in the early 21:st century

Carlsson

2017

Nordic J Health Eco

Self Cite

View full text Add to dashboard Cite

Abstract:What is the actual value of new medicines? The answer to this question is the key to rational use of new technologies in health care and for design of appropriate incentives for innovation. In this paper we present methods, data and study results for valuing new medical technologies in a life cycle perspective, relevant for development of a new approach to contract and payment for innovation that can replace present systems for pricing and reimbursement. Focus is on value in clinical practice, and on the data needs and methods needed for the development of outcome-based payment systems that balances risks and rewards for innovation in health care. We provide an overview of studies from the Swedish context on the value of new medicines introduced in the treatment of diabetes, cancer, cardiovascular disease and rheumatoid arthritis. These studies using national health data and quality registers emphasise the importance of continuing efforts to collect relevant data for assessment of value after a medicine reaches the market and starts to be used in clinical practice. It is only when medicines are used in clinical practice that the benefits for real-world patient populations can be identified, measured and valued. Analyses of real-world data will also assist further development and tailoring of treatment strategies to optimize the value of the new technology. While an effective patent system rewards innovation for a limited period of time, many innovations may continue to provide value to society long after patent protection, and these values must be included in the assessment of value of innovation. JEL classification: I11, O32, O33

show abstract

“…1,2 Statins inhibit 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) a rate limiting step in the conversion of HMG-CoA to mevalonate, a precursor for several cellular processes. One result of HMGCR inhibition is reduced cholesterol biosynthesis and coupled with increased LDL-receptor mediated sequestration of LDL, statins are effective at lowering circulating LDL-cholesterol levels.…”

Section: Statins Cholesterol and Inflammationmentioning

confidence: 99%